NEWS

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

May 28, 2019

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

Read More

Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals.

May 16, 2019

Research paper published in the American Journal of Clinical Nutrition

Read More

Israel’s Zebra Medical gets FDA ok for AI chest X-ray product

May 13, 2019

Zebra Medical Vision said on Monday it received approval from the U.S. Food and Drug Administration for its artificial intelligence-based chest X-ray triage product.

Read More

Computational Pathology Pioneer Ibex Raises $11M

March 26, 2019

aMoon Fund leads round into developer of first ever clinically deployed AI Based Cancer Diagnosis system

Read More

Israeli migraine device co Theranica raises $35m

March 18, 2019

Nerivio Migra, the Netanya-based company’s novel remote neuromodulation device for acute treatment of migraine, is under review by the FDA.

Read More

Israeli health fund aMoon II raises $660 million

March 6, 2019

Israel-based healthcare fund aMoon II said on Wednesday it has received commitments of $660 million from investors. This is up from $600 million reported in January in an investor document obtained by Reuters.

Read More

A healthcare investment fund has become one of Israel’s largest with a $660 million close

March 6, 2019

One of Israel’s single largest venture capital funds is a new later stage vehicle focused on healthcare.

Read More

Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma

March 4, 2019

Results support the clinical development of AL101 as a targeted monotherapy for people with tumors bearing Notch activated mutations

Read More

Regenera Pharma Enrolls First Patient in US Phase 3 Study of RPh201 in NAION

August 2, 2018

Advances Phase 2 Study in Alzheimer’s Disease in Canada, RPh201 development in US supported by Fast Track Designation by US Food and Drug Administration

Read More

Israeli firm creates particles to kill germs on contact, fight bacterial disease

August 2, 2018

With product initially aimed for dental industry, Petah-Tikva based Nobio raises $3.6 million from aMoon Fund and Dr. Ole Jensen, a US surgeon and dentist

Read More

Zebra Medical Vision gets $30M Series C to create AI-based tools for radiologists

June 7, 2018

Zebra Medical Vision, an Israeli medical imaging startup that uses machine and deep learning to build tools for radiologists, has raised a $30 million Series C led by health technology fund aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation—JJDC Inc.

Read More

Medial EarlySign’s clinical validation trial shows promise for detecting colorectal cancer

April 17, 2018

A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.

Read More

BiondVax, NIAID kick off phase 2 universal flu vaccine study in U.S.

April 11, 2018

Already gearing up for a late-stage universal flu vaccine test in European countries, BiondVax has attracted its first participant to a phase 2 study sponsored by the National Institute of Allergy and Infectious Diseases.

Read More

Mylan to Acquire the Global Marketing Rights to Glatiramer Acetate Product through Mapi Pharma

April 10, 2018

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis.

Read More

Ayala notches up $17M in financing to push BMS drug into phase 2

April 10, 2018

Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing.

Read More

Pharma Two B Doses First Patients in Early-stage Parkinson’s Phase 3 Trial

February 12, 2018

Israel’s Pharma Two B has dosed the first patients in a Phase 3 trial to evaluate the safety and efficacy of its drug candidate P2B001 to treat early-stage Parkinson’s disease.

Read More

Additional Strategic Funding for CartiHeal’s Ongoing AGILI-C™ IDE Clinical Study

January 31, 2018

KFAR SABA, Israel & DURHAM, N.C.–(BUSINESS WIRE)–CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5M investment from Bioventus, a global leader in orthobiologics – reflecting the growing interest in CartiHeal’s technology.

Read More

Pharma Two B Ltd. Closes $30 Million Financing Round

January 23, 2018

REHOVOTH, Israel, Feb. 27, 2017 /PRNewswire/ — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and…

Read More

Marius Nacht to invest $20m in Regenera

January 2, 2018

aMoon Partners, controlled and managed by by Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, together with Dr. Yair Schindel, is likely to invest $20 million more in pharma company Regenera, in which InterCure Ltd. (TASE: INCR-L) owns a 23.48% stake. According to the proposal, aMoon will invest $10 million now and $10 million more as needed.

Read More

Nacht, Harel Insurance invest in personalized cancer treatment

December 7, 2017

Ayala Pharmaceuticals has bought rights from international company Bristol-Myers Squibb (BMS) to develop a personalized treatment for cancer. Ayala, founded a few months ago for this purpose, is an initiative by the Israel Biotech Fund, led by Dr. David Sidransky, Dr. Yuval Cabilly, and Ido Zairi. The fund recruited the aMoon Partners fund (led by Check…

Read More